Everand Logo

Welcome to Everand!

  • STAT

    Listen: Drug pricing partisanship, tech’s march into health care, and Tinder for clinical trials

    Has drug price reform already stalled? How far has tech come in medicine? All that and more on the new episode of our #biotech #podcast, "The Readout LOUD."
    by Damian Garde and Rebecca Robbins May 16, 2019 1 minute

    Has drug price reform already stalled? How far has tech come in medicine? And should there be an app for ?

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About MorphoSys Drug Risks, An AstraZeneca Admission, And More
    MorphoSys is dealing with a safety issue with pelabresib, the experimental treatment for myelofibrosis and centerpiece of its proposed $3 billion acquisition by Novartis.
    STAT2 min readCrime & Violence
    STAT+: Pharmalittle: We’re Reading About A Medicare Price-negotiation Ruling, Pharma’s Slipping Reputation, And More
    A U.S. judge dealt a blow to two drugmakers challenging the authority for Medicare to negotiate the prices of prescription drugs.
    STAT2 min readAmerican Government
    STAT+: Pharmalittle: We’re Reading About FTC Reviewing Novo-Catalent Deal, Amneal Opioid Settlement, And More
    The FTC wants more information on a $16.5 million deal in which Novo Nordisk's parent company would purchase Catalent, a contract drug manufacturer.

    Related Books & Audiobooks